CEL-SCI (NYSE:CVM) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM) in a report released on Tuesday. The brokerage set a “sell” rating on the stock.

CEL-SCI Stock Down 5.6 %

Shares of CVM opened at $0.34 on Tuesday. The firm has a market cap of $26.14 million, a PE ratio of -0.71 and a beta of 0.69. The company’s fifty day moving average is $0.44 and its two-hundred day moving average is $0.75. CEL-SCI has a fifty-two week low of $0.33 and a fifty-two week high of $2.50. The company has a quick ratio of 1.09, a current ratio of 1.07 and a debt-to-equity ratio of 0.66.

Hedge Funds Weigh In On CEL-SCI

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in shares of CEL-SCI by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after acquiring an additional 53,879 shares in the last quarter. Thoroughbred Financial Services LLC lifted its holdings in shares of CEL-SCI by 40.1% during the 4th quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock valued at $76,000 after acquiring an additional 54,900 shares in the last quarter. Finally, Plotkin Financial Advisors LLC acquired a new position in shares of CEL-SCI during the 3rd quarter valued at $98,000. Institutional investors and hedge funds own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.